TechMARK movers: Elan narrows loss

LONDON (ShareCast) – Irish drug firm Elan saw net losses narrow to $68.2m from $71.5m in the second quarter thanks to a rise in revenues. Revenues were up by 14%, led by a 30% increase in sales from Tysabri and a 10% increase in revenues from EDT. For

Leave a Reply